Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 75, Issue 2, 2010, Pages 152-159

  Mohile, Supriya Gupta ^a   Lacy, Maureen ^b   Rodin, Miriam ^c   Bylow, Kathryn ^d   Dale, William ^b   Meager, Michael R ^b   Stadler, Walter M ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Androgen deprivation; Cognition; Elderly; Prostate

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; BRAIN DISEASE; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; FUNCTIONAL ASSESSMENT; HUMAN; LANGUAGE ABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL CAPACITY; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; TUMOR ABLATION; CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; LONGITUDINAL STUDY; MIDDLE AGED; PHYSIOLOGY; PILOT STUDY; PROSTATIC NEOPLASMS; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CARCINOMA; COGNITION; COHORT STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PROSTATIC NEOPLASMS;

EID: 77955024632     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.06.009     Document Type: Review

References (35)

1. Beedassy A., Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 1996, 26:428-438.
2. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337(5):295-300.
3. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7(6):472-479.
4. Granfors T., Modig H., Damber J.E., Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998, 159(6):2030-2034.
5. Basaria S., Dobs A.S. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999, 15(2):131-142.
6. Basaria S., Lieb J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56(6):779-786.
7. Nelson C.J., Lee J.S., Gamboa M.C., Roth A.J. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008, 113(5):1097-1106.
8. Plassman B.L., Langa K.M., Fisher G.G., et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29(1-2):125-132.
9. Plassman B.L., Langa K.M., Fisher G.G., et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 2008, 148(6):427-434.
10. Kelley B.J., Petersen R.C. Alzheimer's disease and mild cognitive impairment. Neurol Clin 2007, 25(3):577-609. v.
11. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256(3):183-194.
12. Petersen R.C. Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007, 27(1):22-31.
13. Petersen R.C., Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol 2001, 58(12):1985-1992.
14. Reitan R.M. The relation of the trail making test to organic brain damage. J Consult Psychol 1955, 19(5):393-394.
15. Lemay S., Bedard M.A., Rouleau I., Tremblay P.L. Practice effect and test-retest reliability of attentional and executive tests in middle-aged to elderly subjects. Clin Neuropsychol 2004, 18(2):284-302.
16. Meyers J., Meyers K. Rey Complex Figure Test and Recognition Trial. Professional Manual 1995, Psychological Assessment Resources, Palo Alto.
17. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol 1991, 5:125-142.
18. Shapiro A.M., Benedict R.H., Schretlen D., Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 1999, 13(3):348-358.
19. Benedict R.H., Schretlen D., Groniger L. Revision of the Brief Visual-Spatial Memory Test: studies of normal performance, reliability, and validity. Psychol Assess 1996, 8:145-153.
20. Vega A. Use of Purdue pegboard and figger tapping performance as a apid screening test for brain damage. J Clin Psychol 1969, 25:255-258.
21. Gallagher D., Nies G., Thompson L.W. Reliability of the Beck Depression Inventory with older adults. J Consult Clin Psychol 1982, 50(1):152-153.
22. Gallagher D., Breckenridge J., Steinmetz J., Thompson L. The Beck Depression Inventory and Research Diagnostic Criteria: congruence in an older population. J Consult Clin Psychol 1983, 51(6):945-946.
23. Kendall P.C., Finch A.J., Auerbach S.M., Hooke J.F., Mikulka P.J. The State-Trait Anxiety Inventory: a systematic evaluation. J Consult Clin Psychol 1976, 44(3):406-412.
24. Frerichs R.J., Tuokko H.A. Reliable change scores and their relation to perceived change in memory: implications for the diagnosis of mild cognitive impairment. Arch Clin Neuropsychol 2006, 21(1):109-115.
25. Jacobson N.S., Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991, 59(1):12-19.
26. Jenkins V.A., Bloomfield D.J., Shilling V.M., Edginton T.L. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 2005, 96(1):48-53.
27. Chertkow H., Massoud F., Nasreddine Z., et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ 2008, 178(10):1273-1285.
28. Tierney M.C., Yao C., Kiss A., McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005, 64(11):1853-1859.
29. Spaan P.E., Raaijmakers J.G., Jonker C. Early assessment of dementia: the contribution of different memory components. Neuropsychology 2005, 19(5):629-640.
30. Ivnik R.J., Smith G.E., Petersen R.C., et al. Diagnostic accuracy of four approaches to interpreting neuropsychological test data. Neuropsychology 2000, 14(2):163-177.
31. Kayl A.E., Wefel J.S., Meyers C.A. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther 2006, 13(4):362-369.
32. Zehnder A.E., Blasi S., Berres M., Spiegel R., Monsch A.U. Lack of practice effects on neuropsychological tests as early cognitive markers of Alzheimer disease?. Am J Alzheimers Dis Other Demen 2007, 22(5):416-426.
33. Salminen E., Portin R., Korpela J., et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 2003, 89(6):971-976.
34. Green H.J., Pakenham K.I., Headley B.C., et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 2004, 93(7):975-979.
35. Mohile S.G., Bylow K., Dale W., et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 2007, 109(4):802-810.